Volume 141, Issue 2, Pages (February 2012)

Slides:



Advertisements
Similar presentations
Pulmonary hypertension Goal directed therapy Pulmonary Hypertension Programme University of Toronto FMD.
Advertisements

Goldberg Linn , M.D., Elliot Diane L. , M.D., Kuehl Kerry S. , M.S. 
Tell-tale Telangiectasias
Colloquium on Therapy of Right Heart Failure
When to Be Rash About a Fever and Headache
Volume 56, Issue 1, Pages (July 1969)
Causes of Pulmonary Hypertension in the Elderly
Timothy W. Higenbottam, MD, FCCP, Elizabeth A. Laude, PhD  CHEST 
Hyperbaric Oxygenation in Cardiac and Pulmonary Disease
Varicosities of the Pulmonary Veins
Exercise Conditioning and Cardiopulmonary Fitness in Cystic Fibrosis
Volume 127, Issue 6, Pages (June 2005)
Air Pollution and Chest Disease
Epidemiologic Studies of Air Pollution*
Navin K. Jain, MD, Thiam H. Lie, MD, FCCP  CHEST 
REVEAL Registry PAH Risk Score Calculator
Oxygen Therapy Titrated to Raise Mixed Venous Oxygen Content in COPD
Valve Drainage of the Pleural Cavity
Limitations of right heart catheterization in the diagnosis and risk stratification of patients with pulmonary hypertension related to left heart disease:
Advance Directive Education During Pulmonary Rehabilitation
Volume 148, Issue 5, Pages (November 2015)
Volume 71, Issue 3, Pages (March 1977)
Effects of Long-term Infusion of Prostacyclin on Exercise Performance in Patients With Primary Pulmonary Hypertension  Wax David , MD, Garofano Robert.
Volume 142, Issue 1, Pages (July 2012)
Breath Analysis in Pulmonary Arterial Hypertension
Volume 151, Issue 3, Pages (March 2017)
A contemporary analysis of pulmonary hypertension in patients undergoing mitral valve surgery: Is this a risk factor?  Daniel H. Enter, MD, Anthony Zaki,
Baseline and Serial Brain Natriuretic Peptide Level Predicts 5-Year Overall Survival in Patients With Pulmonary Arterial Hypertension: Data From the REVEAL.
Volume 143, Issue 5, Pages e166S-e190S (May 2013)
Mitral stenosis with pulmonary hypertension: We should operate early
CHA2DS2-VASc Score Is Directly Associated with the Risk of Pulmonary Embolism in Patients with Atrial Fibrillation  Walid Saliba, MD, MPH, Gad Rennert,
Arterial Line or Cuff BP?
Exercise-Induced Pulmonary Hypertension
Volume 143, Issue 5, Pages e166S-e190S (May 2013)
Krishman. Padmanabhan, M.D., F.C.C.P., Santi R. Dhar, M.D., F.C.C.P 
Has the 6-Min Walk Distance Run Its Course?
Arjun Pennathur, MD, Liqiang Xi, MD, Virginia R. Litle, MD, William E
Counterpoint: Adherence to Early Goal-Directed Therapy
Volume 154, Issue 4, Pages (October 2018)
Five-Year Outcomes of Patients Enrolled in the REVEAL Registry
Apnea in the Nonobese CHEST Volume 153, Issue 4, (April 2018)
Volume 126, Issue 1, Pages 14S-34S (July 2004)
Idiopathic Pulmonary Arterial Hypertension in Asians
Volume 146, Issue 6, Pages (December 2014)
Volume 146, Issue 5, Pages (November 2014)
Imaging for the Management of Community-Acquired Pneumonia
Prognosis of Pulmonary Arterial Hypertension*
Risk Stratification and Interventional Cardiology: Robert L
REVEAL pulmonary arterial hypertension (PAH) risk score.
Michael D. McGoon, MD, Abby Krichman, RRT, Harrison W
Rebuttal From Dr Mazzone
Cox proportional hazard estimates for multivariate model of survival, limited to terms included in the final stepwise model. Cox proportional hazard estimates.
Inclusion characteristics of a) previously diagnosed and b) newly diagnosed pulmonary arterial hypertension (PAH) patients enrolled in REVEAL. PVR: pulmonary.
An expert proposal for a treat-to-target checklist for pulmonary arterial hypertension (PAH). An expert proposal for a treat-to-target checklist for pulmonary.
Bedside Calibration Of Pulmonary Artery Catheters
Invasive Pulmonary Aspergillosis
Volume 146, Issue 6, Pages (December 2014)
Pulmonary Manifestations in a Case of Multiple Myeloma
Volume 147, Issue 2, Pages (February 2015)
Volume 149, Issue 4, Pages e103-e105 (April 2016)
Simplified REVEAL (Registry to Evaluate Early And Long-term PAH Disease Management) risk score. Simplified REVEAL (Registry to Evaluate Early And Long-term.
Predicting Survival in Patients With Pulmonary Arterial Hypertension
Volume 42, Issue 2, Pages (August 1962)
COUNTERPOINT: Does Interstitial Pneumonia With Autoimmune Features Represent a Distinct Class of Patients With Idiopathic Interstitial Pneumonia? No 
Volume 133, Issue 4, Pages (April 2008)
Systemic Inflammation, COPD, and Pulmonary Hypertension
How to Screen for PAH in Scleroderma-Spectrum Disorders
Arterial Line or Cuff BP?
Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort. Module 2: evaluation of the REVEAL risk score in the FPHN validation cohort.
Schematic diagram of the DETECT study [56].
Presentation transcript:

Volume 141, Issue 2, Pages 354-362 (February 2012) The REVEAL Registry Risk Score Calculator in Patients Newly Diagnosed With Pulmonary Arterial Hypertension  Raymond L. Benza, MD, Mardi Gomberg-Maitland, MD, FCCP, Dave P. Miller, MS, Adaani Frost, MD, FCCP, Robert P. Frantz, MD, Aimee J. Foreman, MA, David B. Badesch, MD, FCCP, Michael D. McGoon, MD, FCCP  CHEST  Volume 141, Issue 2, Pages 354-362 (February 2012) DOI: 10.1378/chest.11-0676 Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 1 REVEAL Registry PAH risk score calculator. Calculated risk scores can range from 0 (lowest risk) to 22 (highest risk). If N-terminal proBNP is available and BNP is not, listed cut points are replaced with < 300 pg/mL and > 1500 pg/mL. APAH = associated pulmonary arterial hypertension; BNP = brain natriuretic peptide; BPM = beats per minute; CTD = connective tissue disease; DLco = diffusing capacity of lung for carbon monoxide; FPAH = familial pulmonary arterial hypertension; HR = heart rate; mRAP = mean right atrial pressure; NYHA = New York Heart Association; PAH = pulmonary arterial hypertension; PoPH = portopulmonary hypertension; PVR = pulmonary vascular resistance; REVEAL Registry = Registry to Evaluate Early and Long-term Pulmonary Arterial Hypertension Disease Management; SBP = systolic BP; WHO = World Health Organization. CHEST 2012 141, 354-362DOI: (10.1378/chest.11-0676) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 2 Twelve-month Kaplan-Meier survival estimate for the REVEAL Registry development cohort with predicted risk score. Risk strata are indicated by the lines: predicted 1-year survival is 95% to 100% in the low-risk group, 90% to < 95% in the average-risk group, 85% to < 90% in the moderately high-risk group, 70% to < 85% in the high-risk group, and < 70% in the very high-risk group. See Figure 1 legend for expansion of abbreviation. CHEST 2012 141, 354-362DOI: (10.1378/chest.11-0676) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 3 A, One-year survival in the validation cohort stratified according to estimated probability of surviving 1 year. Predicted 1-year survival is 95% to 100% in the low-risk group, 90% to < 95% in the average-risk group, 85% to < 90% in the moderately high-risk group, 70% to < 85% in the high-risk group, and < 70% in the very high-risk group. B, One-year survival in the validation cohort stratified according to risk score. The average predicted 1-year survival is 95% to 100% (low risk) for patients with risk scores of 1 to 7. Similarly, the ranges specified for average risk, moderately high risk, high risk, and very high risk correspond to risk scores of 8, 9, 10 to 11, and ≥ 12. CHEST 2012 141, 354-362DOI: (10.1378/chest.11-0676) Copyright © 2012 The American College of Chest Physicians Terms and Conditions

Figure 4 Model calibration plots. A, Observed 1-year Kaplan-Meier estimates vs 1-year survival predicted by the prognostic equation. The Xs correspond to the observed survival in the five risk strata based on the prognostic equation. Predicted 1-year survival is 95% to 100% in the low-risk group, 90% to < 95% in the average-risk group, 85% to < 90% in the moderately high-risk group, 70% to < 85% in the high-risk group, and < 70% in the very high-risk group. B, Xs correspond to the observed survival in the five risk strata based on the risk score. Risk score ranges are 1 to 7 in the low-risk group, 8 in the average-risk group, 9 in the moderately high-risk group, 10 to 11 in the high-risk group, and ≥ 12 in the very high-risk group. CHEST 2012 141, 354-362DOI: (10.1378/chest.11-0676) Copyright © 2012 The American College of Chest Physicians Terms and Conditions